Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Subscribe To Our Newsletter & Stay Updated
